DHL Global Forwarding has significantly expanded its DHL Health Logistics Cold Chain Network by establishing six new dedicated air corridors. These routes are designed to enhance the transportation of Life Sciences & Healthcare (LSH) products, connecting major pharmaceutical and healthcare centers in Europe and North America with key hubs across Asia.
The newly introduced air corridors include Liège (Belgium) to Shanghai (China), Brussels (Belgium) to Shanghai (China), Brussels (Belgium) to Singapore, Cincinnati (USA) to Singapore, Cincinnati (USA) to Tokyo Narita (Japan), and Cincinnati (USA) to Seoul Incheon (South Korea). This expansion aims to provide more robust and reliable cold chain solutions for temperature-sensitive pharmaceuticals and healthcare goods.
For freight forwarders and operations managers, this development means increased capacity and improved schedule reliability for critical pharma and healthcare shipments on these specific trade lanes. The establishment of dedicated corridors suggests a focus on specialized handling and potentially more consistent transit times, which is crucial for high-value, time-sensitive, and temperature-controlled cargo. It may also offer more direct routing options, potentially reducing transshipment risks and overall lead times for clients in the life sciences sector.
This strategic expansion by DHL Global Forwarding is expected to bolster its position in the global pharma logistics market, offering enhanced service levels for pharmaceutical companies and healthcare providers moving goods between these critical regions.
